P
Palladio Biosciences
Biotechnology company with a mission to develop transformative medicines for orphan diseases of the kidney
About Palladio Biosciences
Palladio Biosciences is a biopharmaceutical company focused on developing innovative treatments for autosomal dominant polycystic kidney disease (ADPKD), a serious genetic disorder that leads to kidney failure. The company's lead drug candidate, lixivaptan, is currently in Phase 3 clinical trials. Lixivaptan aims to provide a safer alternative to existing treatments by reducing liver toxicity, a significant side effect associated with the only currently approved medication for ADPKD. Palladio Biosciences serves patients diagnosed with ADPKD, a market with over 140,000 individuals in the United States alone. The company operates within the biopharmaceutical sector, focusing on research and development to bring new therapies to market. Palladio's business model involves conducting clinical trials to demonstrate the safety and efficacy of lixivaptan, with the goal of obtaining regulatory approval and commercializing the drug. Revenue generation will primarily come from the sale of lixivaptan upon approval. The company is also exploring additional indications and potential partnerships to expand its market reach.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 55.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Feb 2021 | $0 | — | Centessa Pharmaceuticals | ↗ |
| SERIES B✓Equity / VC | Sep 2020 | $20M | $80M | Roche Venture Fund · Samsara BioCapital · Osage University Partners · Medicxi | — |
Growth signals
Latest recorded traffic for Palladio Biosciences is 3.6K monthly website visits, up 2150% over the last three months. Palladio Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Palladio Biosciences in the Washington DC ecosystem
The Palladio Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Medicxi
Samsara BioCapital
Roche Venture Fund
Osage University Partners
Other known investors1 additional known investor
Centessa Pharmaceuticals
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Palladio Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Palladio Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









